FGF/FGFR1 system in paired breast tumor-adjacent and tumor tissues, associations with mammographic breast density and tumor characteristics.
FGFR1
breast cancer
fibroblast growth factor receptor
mammographic breast density
tumor characteristics
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
29
05
2023
accepted:
04
07
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Mammographic breast density (MBD) is an established breast cancer risk factor, yet the underlying molecular mechanisms remain to be deciphered. Fibroblast growth factor receptor 1 (FGFR1) amplification is associated with breast cancer development and aberrant FGF signaling found in the biological processes related to both high mammographic density and breast cancer microenvironment. The aim of this study was to investigate the FGF/FGFR1 expression in-between paired tumor-adjacent and tumor tissues from the same patient, and its associations with MBD and tumor characteristics. FGFR1 expression in paired tissues from 426 breast cancer patients participating in the Karolinska Mammography Project for Risk Prediction of Breast Cancer (KARMA) cohort study was analyzed by immunohistochemistry. FGF ligand expression was obtained from RNA-sequencing data for 327 of the included patients. FGFR1 levels were differently expressed in tumor-adjacent and tumor tissues, with increased FGFR1 levels detected in 58% of the tumors. High FGFR1 expression in tumor tissues was associated with less favorable tumor characteristics; high histological grade (OR=1.86, 95% CI 1.00-3.44), high Ki67 proliferative index (OR=2.18, 95% CI 1.18-4.02) as well as tumors of Luminal B-like subtype (OR=2.56, 95%CI 1.29-5.06). While no clear association between FGFR1 expression and MBD was found, FGF ligand (FGF1, FGF11, FGF18) expression was positively correlated with MBD. Taken together, these findings support a role of the FGF/FGFR1 system in early breast cancer which warrants further investigation in the MBD-breast cancer context.
Identifiants
pubmed: 37546410
doi: 10.3389/fonc.2023.1230821
pmc: PMC10400328
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1230821Informations de copyright
Copyright © 2023 Boraka, Klintman, Vallon-Christersson, Zackrisson, Hall, Borgquist and Rosendahl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cell Physiol Biochem. 2018;49(3):1019-1032
pubmed: 30196303
Diagn Interv Imaging. 2017 Mar;98(3):179-190
pubmed: 28131457
Breast Cancer Res. 2007;9(2):R23
pubmed: 17397528
J Clin Pathol. 2022 Jul;75(7):459-464
pubmed: 33753561
Breast Cancer Res Treat. 2018 Jun;169(2):371-379
pubmed: 29392583
Br J Cancer. 2005 Aug 22;93(4):387-91
pubmed: 16106245
N Engl J Med. 2007 Jan 18;356(3):227-36
pubmed: 17229950
Mol Cancer Res. 2021 Jan;19(1):136-149
pubmed: 33033110
Int J Cancer. 2023 Jun 1;152(11):2362-2372
pubmed: 36637153
Cochrane Database Syst Rev. 2019 Apr 29;4:CD012191
pubmed: 31032883
Signal Transduct Target Ther. 2020 Sep 2;5(1):181
pubmed: 32879300
Genome Med. 2015 Feb 02;7(1):20
pubmed: 25722745
J Steroid Biochem Mol Biol. 2022 Oct;223:106132
pubmed: 35659529
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Appl Immunohistochem Mol Morphol. 2022 Oct 1;30(9):600-608
pubmed: 36083147
Cell Cycle. 2014;13(4):580-99
pubmed: 24434780
FASEB J. 1997 Jan;11(1):51-9
pubmed: 9034166
Nature. 2007 Jun 28;447(7148):1087-93
pubmed: 17529967
Nature. 2022 Nov;611(7936):594-602
pubmed: 36352222
Cancer Prev Res (Phila). 2018 Jun;11(6):317-326
pubmed: 29483073
Br J Cancer. 2022 Nov;127(11):2025-2033
pubmed: 36138072
Cancer Epidemiol Biomarkers Prev. 2006 Jun;15(6):1159-69
pubmed: 16775176
NPJ Breast Cancer. 2022 Aug 16;8(1):94
pubmed: 35974007
J Microbiol. 2022 Nov;60(11):1086-1094
pubmed: 36318359
Breast Cancer Res. 2012 Aug 03;14(4):R115
pubmed: 22863309
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Breast Cancer Res Treat. 2020 Nov;184(2):311-324
pubmed: 32852708
Mod Pathol. 2010 Feb;23(2):251-9
pubmed: 19935641
Cancers (Basel). 2022 Apr 13;14(8):
pubmed: 35454864
Front Med (Lausanne). 2017 Dec 08;4:227
pubmed: 29276709
Int J Epidemiol. 2017 Dec 1;46(6):1740-1741g
pubmed: 28180256
Cancer Prev Res (Phila). 2022 Jun 2;15(6):391-398
pubmed: 35288741
Cancer Res. 2010 Mar 1;70(5):2085-94
pubmed: 20179196
Clin Cancer Res. 2016 Jan 1;22(1):259-67
pubmed: 26373574
J Clin Oncol. 2021 Jun 10;39(17):1899-1908
pubmed: 33734864
Oncogene. 2014 Jun 26;33(26):3411-21
pubmed: 23975425
Oncotarget. 2016 Jan 26;7(4):5063-73
pubmed: 26673008
Clin Cancer Res. 2021 Aug 1;27(15):4379-4396
pubmed: 34011560
Cells. 2020 Feb 27;9(3):
pubmed: 32120856
Cell Syst. 2017 Oct 25;5(4):386-398.e4
pubmed: 29032074